The Impact of Cytomegalovirus Reactivation on Cytomegalovirus-Specific Immune Reconstitution in Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis
Open Forum Infectious Diseases · 30.03.2026 · 13 (4)
DOI: 10.1093/ofid/ofag160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 26.03.2026. Verfasst von Cen Jiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University Medical School, Shanghai, PR China. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Cytomegalovirus (CMV) remains the most common viral infection after hematopoietic stem cell transplantation (HSCT). The clinical significance of different CMV DNA forms remains unclear, particularly regarding CMV-specific immune reconstitution.
Methods
A total of 76 HSCT recipients were enrolled. A quantitative DNase I–resistant CMV-DNA assay was performed to distinguish infectious from noninfectious CMV DNA. Based on DNase treatment results, patients were divided into 3 groups: (1) negative DNAemia (ND, n = 25): with no detectable CMV DNA; (2) DNase I-sensitive DNAemia (DSD, n = 26): with only DNase I-sensitive CMV DNA detected; (3) DNase I-resistant DNAemia (DRD, n = 25): with at least one episode of DNase I-resistant CMV DNAemia within 100 days posttransplant. CMV-specific T-cell responses were evaluated by multiparameter flow cytometry, and cytokine polyfunctionality was quantified using Combinatorial Polyfunctionality Analysis of Antigen-Specific T-cell Subsets analysis.
Results
Early CMV reactivation was associated with stronger CD8+ than CD4+ T-cell responses. DNase I–resistant DNAemia patients exhibited significantly enhanced polyfunctional CD8+ T-cell responses compared with ND patients, while DSD patients did not. Among patients with detectable CMV DNA, stronger CD8+ T-cell responses correlated with higher peak viral loads and greater viral shedding. Elevated CMV-specific CD4+ T-cell responses were associated with higher peak CMV-DNA loads and reduced risk of CMV reactivation after day 100 posttransplant. In multivariable analysis, acute graft versus host disease was an independent risk factor for CMV reactivation.
Conclusions
Cytomegalovirus-specific immune reconstitution appears delayed in DSD compared with DRD patients, potentially reflecting limited exposure to replication-competent virus. Assessment of CMV-specific T-cell polyfunctionality may help identify HSCT recipients at increased risk for late CMV reactivation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University Medical School, Shanghai, PR China.
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR…
ORCID-Profile: Lilan Jin, Xiaoxia Hu, Gang Cai
Zitieren
APA
Jiang, C., Jin, L., Wang, L., Gu, Y., Hu, X., & Cai, G. (2026). The Impact of Cytomegalovirus Reactivation on Cytomegalovirus-Specific Immune Reconstitution in Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis. Open Forum Infectious Diseases, 13(4). https://doi.org/10.1093/ofid/ofag160
Vancouver
Jiang C, Jin L, Wang L, Gu Y, Hu X, Cai G. The Impact of Cytomegalovirus Reactivation on Cytomegalovirus-Specific Immune Reconstitution in Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis. Open Forum Infectious Diseases. 2026;13(4). doi:10.1093/ofid/ofag160
BibTeX
@article{Jiang2026,
author = {Jiang, Cen and Jin, Lilan and Wang, Luxiang and Gu, Yanying and Hu, Xiaoxia and Cai, Gang},
title = {The Impact of Cytomegalovirus Reactivation on Cytomegalovirus-Specific Immune Reconstitution in Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis},
journal = {Open Forum Infectious Diseases},
year = {2026},
volume = {13},
number = {4},
doi = {10.1093/ofid/ofag160}
}
EUVIMED